Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Development of a POC test for TB based on multiple immunodominant epitopes of M. tuberculosis specific cell-wall proteins.

Gonzalez JM, Francis B, Burda S, Hess K, Behera D, Gupta D, Agarwal AN, Verma I, Verma A, Myneedu VP, Niedbala S, Laal S.

PLoS One. 2014 Sep 23;9(9):e106279. doi: 10.1371/journal.pone.0106279. eCollection 2014.

2.

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.

Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.

J Infect Dis. 2013 Jun 15;207 Suppl 2:S70-7. doi: 10.1093/infdis/jit114.

3.

Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies.

Haldar B, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny MK, Nyambi P.

PLoS One. 2011 Feb 23;6(2):e17253. doi: 10.1371/journal.pone.0017253.

4.

HIV-1 reverse transcriptase drug-resistance mutations in chronically infected individuals receiving or naïve to HAART in Cameroon.

Burda ST, Viswanath R, Zhao J, Kinge T, Anyangwe C, Tinyami ET, Haldar B, Powell RL, Jarido V, Hewlett IK, Nyambi PN.

J Med Virol. 2010 Feb;82(2):187-96. doi: 10.1002/jmv.21677.

5.

Comparative analysis of cell culture and prediction algorithms for phenotyping of genetically diverse HIV-1 strains from Cameroon.

Ragupathy V, Zhao J, Wang X, Wood O, Lee S, Burda S, Nyambi P, Hewlett I.

AIDS Res Ther. 2009 Nov 25;6:27. doi: 10.1186/1742-6405-6-27.

6.

High frequency of HIV-1 dual infections among HIV-positive individuals in Cameroon, West Central Africa.

Powell RL, Urbanski MM, Burda S, Kinge T, Nyambi PN.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):84-92. doi: 10.1097/QAI.0b013e31818d5a40.

PMID:
19295338
7.

Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Nyambi P, Burda S, Urbanski M, Heyndrickx L, Janssens W, Vanham G, Nadas A.

AIDS Res Hum Retroviruses. 2008 Dec;24(12):1507-19. doi: 10.1089/aid.2008.0154.

8.

Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Gorny MK, Wang XH, Williams C, Volsky B, Revesz K, Witover B, Burda S, Urbanski M, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S, Nadas A.

Mol Immunol. 2009 Feb;46(5):917-26. doi: 10.1016/j.molimm.2008.09.005. Epub 2008 Oct 25.

9.

Utility of the heteroduplex assay (HDA) as a simple and cost-effective tool for the identification of HIV type 1 dual infections in resource-limited settings.

Powell RL, Urbanski MM, Burda S, Nanfack A, Kinge T, Nyambi PN.

AIDS Res Hum Retroviruses. 2008 Jan;24(1):100-5. doi: 10.1089/aid.2007.0162.

PMID:
18275354
10.

Identification of a novel circulating recombinant form (CRF) 36_cpx in Cameroon that combines two CRFs (01_AE and 02_AG) with ancestral lineages of subtypes A and G.

Powell RL, Zhao J, Konings FA, Tang S, Nanfack A, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN.

AIDS Res Hum Retroviruses. 2007 Aug;23(8):1008-19.

PMID:
17725418
11.

Circulating recombinant form (CRF) 37_cpx: an old strain in Cameroon composed of diverse, genetically distant lineages of subtypes A and G.

Powell RL, Zhao J, Konings FA, Tang S, Ewane L, Burda S, Urbanski MM, Saa DR, Hewlett I, Nyambi PN.

AIDS Res Hum Retroviruses. 2007 Jul;23(7):923-33.

PMID:
17678477
12.

Quasispecies analysis of novel HIV-1 recombinants of subtypes A and G reveals no similarity to the mosaic structure of CRF02_AG.

Powell RL, Konings FA, Nanfack A, Burda S, Urbanski MM, Saa D, Nyambi PN.

J Med Virol. 2007 Sep;79(9):1270-85.

PMID:
17607774
13.

Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1.

Gorny MK, Williams C, Volsky B, Revesz K, Wang XH, Burda S, Kimura T, Konings FA, Nádas A, Anyangwe CA, Nyambi P, Krachmarov C, Pinter A, Zolla-Pazner S.

J Virol. 2006 Jul;80(14):6865-72.

14.

Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.

Kelly HR, Urbanski M, Burda S, Zhong P, Konings F, Nanfack J, Tongo M, Kinge T, Achkar J, Nyambi P.

Hum Antibodies. 2005;14(3-4):89-99.

PMID:
16720979
15.

Genetic analysis of HIV-1 strains in rural eastern Cameroon indicates the evolution of second-generation recombinants to circulating recombinant forms.

Konings FA, Haman GR, Xue Y, Urbanski MM, Hertzmark K, Nanfack A, Achkar JM, Burda ST, Nyambi PN.

J Acquir Immune Defic Syndr. 2006 Jul;42(3):331-41.

PMID:
16639350
16.
17.
18.

HIV-1 CRF09_cpx circulates in the North West Province of Cameroon where CRF02_AG infections predominate and recombinant strains are common.

Burda ST, Konings FA, Williams CA, Anyangwe C, Nyambi PN.

AIDS Res Hum Retroviruses. 2004 Dec;20(12):1358-63.

PMID:
15650429
19.

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.

20.

Infection with HIV type 1 group M non-B subtypes in individuals living in New York City.

Achkar JM, Burda ST, Konings FA, Urbanski MM, Williams CA, Seifen D, Kahirimbanyi MN, Vogler M, Parta M, Lupatkin HC, Zolla-Pazner S, Nyambi PN.

J Acquir Immune Defic Syndr. 2004 Jul 1;36(3):835-44.

PMID:
15213568
21.

Defining human immunodeficiency virus (HIV) type 1 immunotypes with six human monoclonal antibodies.

Nádas A, Zhong P, Burda S, Zekeng L, Urbanski M, Gorny MK, Zolla-Pazner S, Nyambi PN.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):55-65.

PMID:
15000699
22.

Genetic and biological properties of HIV type 1 isolates prevalent in villagers of the Cameroon equatorial rain forests and grass fields: further evidence of broad HIV type 1 genetic diversity.

Zhong P, BUrda S, Konings F, Urbanski M, Ma L, Zekeng L, Ewane L, Agyingi L, Agwara M, Saa, Afane ZE, Kinge T, Zolla-Pazner S, Nyambi P.

AIDS Res Hum Retroviruses. 2003 Dec;19(12):1167-78.

PMID:
14717120
23.

Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China.

Zhong P, Kang L, Pan Q, Konings F, Burda S, Ma L, Xue Y, Zheng X, Jin Z, Nyambi P.

J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):91-101.

PMID:
14501800
24.

HIV infection in rural villages of Cameroon.

Nyambi P, Zekeng L, Kenfack H, Tongo M, Nanfack A, Nkombe I, Ndonko F, Shang J, Burda S, Mbah H, Agyingi L, Zhong P, Nádas A, Zolla-Pazner S, Marmor M.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):506-13.

PMID:
12473839
25.

HIV type 1 group M clades infecting subjects from rural villages in equatorial rain forests of Cameroon.

Zhong P, Burda S, Urbanski M, Kenfack H, Tongo M, Heyndrickx L, Nanfack A, Shang J, Agyingi L, Zolla-Pazner S, Zekeng L, Nyambi P.

J Acquir Immune Defic Syndr. 2002 Dec 15;31(5):495-505.

PMID:
12473838
26.

Predominance of infection with HIV-1 circulating recombinant form CRF02_AG in major Cameroonian cities and towns.

Nyambi P, Heyndrickx L, Vereecken K, Burda S, De Houwer K, Coppens S, Urbanski M, Williams C, Ndumbe P, Janssens W.

AIDS. 2002 Jan 25;16(2):295-6. No abstract available.

PMID:
11807317
27.

Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120.

Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, Burda S, Wang XH, Bandres J, Zolla-Pazner S, Holmes H.

Immunol Lett. 2001 Dec 3;79(3):209-13.

PMID:
11600200
28.

Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades.

Mbah HA, Burda S, Gorny MK, Williams C, Revesz K, Zolla-Pazner S, Nyambi PN.

J Virol. 2001 Aug;75(16):7785-8.

29.

Antioxidant and antiradical activities of flavonoids.

Burda S, Oleszek W.

J Agric Food Chem. 2001 Jun;49(6):2774-9.

PMID:
11409965
30.

A virus binding assay for studying the antigenic landscape on intact, native, primary human immunodeficiency virus-type 1.

Nyambi PN, Burda S, Bastiani L, Williams C.

J Immunol Methods. 2001 Jul 1;253(1-2):253-62.

PMID:
11384686
31.

Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes.

Nyambi PN, Nádas A, Mbah HA, Burda S, Williams C, Gorny MK, Zolla-Pazner S.

J Virol. 2000 Nov;74(22):10670-80.

33.

Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.

Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S.

J Virol. 2000 Aug;74(15):7096-107.

34.

Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines.

Zolla-Pazner S, Xu S, Burda S, Duliege AM, Excler JL, Clements-Mann ML.

J Infect Dis. 1998 Nov;178(5):1502-6.

PMID:
9780275
35.

Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage.

Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S.

J Virol. 1998 Sep;72(9):6988-96.

36.

A human monoclonal antibody specific for the V3 loop of HIV type 1 clade E cross-reacts with other HIV type 1 clades.

Gorny MK, Mascola JR, Israel ZR, VanCott TC, Williams C, Balfe P, Hioe C, Brodine S, Burda S, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):213-21.

PMID:
9491911
37.

Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.

Zolla-Pazner S, Lubeck M, Xu S, Burda S, Natuk RJ, Sinangil F, Steimer K, Gallo RC, Eichberg JW, Matthews T, Robert-Guroff M.

J Virol. 1998 Feb;72(2):1052-9.

38.

Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity.

Gorny MK, VanCott TC, Hioe C, Israel ZR, Michael NL, Conley AJ, Williams C, Kessler JA 2nd, Chigurupati P, Burda S, Zolla-Pazner S.

J Immunol. 1997 Nov 15;159(10):5114-22.

PMID:
9366441
39.

Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.

Hioe CE, Xu S, Chigurupati P, Burda S, Williams C, Gorny MK, Zolla-Pazner S.

Int Immunol. 1997 Sep;9(9):1281-90.

PMID:
9310831
40.

Resting cell neutralization assay for HIV-1 primary isolates.

Hioe C, Burda S, Chigurupati P, Xu S, Zolla-Pazner S.

Methods. 1997 Aug;12(4):300-5.

PMID:
9245610
41.

Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines.

Zolla-Pazner S, Alving C, Belshe R, Berman P, Burda S, Chigurupati P, Clements ML, Duliege AM, Excler JL, Hioe C, Kahn J, McElrath MJ, Sharpe S, Sinangil F, Steimer K, Walker MC, Wassef N, Xu S.

J Infect Dis. 1997 Apr;175(4):764-74.

PMID:
9086128
42.

Functional studies of bispecific antibodies directed against HIV-1 and the Fc gamma I receptor type I.

Gorny MK, Keler T, Burda S, Williams C, Gabriel JL, Mitchell WM, Deo YM, Zolla-Pazner S.

Antibiot Chemother (1971). 1996;48:173-83. No abstract available.

PMID:
8726522
43.

Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry.

Zolla-Pazner S, O'Leary J, Burda S, Gorny MK, Kim M, Mascola J, McCutchan F.

J Virol. 1995 Jun;69(6):3807-15.

44.

Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1.

Gorny MK, Moore JP, Conley AJ, Karwowska S, Sodroski J, Williams C, Burda S, Boots LJ, Zolla-Pazner S.

J Virol. 1994 Dec;68(12):8312-20.

45.

Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.

Laal S, Burda S, Gorny MK, Karwowska S, Buchbinder A, Zolla-Pazner S.

J Virol. 1994 Jun;68(6):4001-8.

46.

Human monoclonal antibodies to HIV-1 define synergistic activities leading to enhanced neutralization.

Zolla-Pazner S, Laal S, Burda S, Buchbinder A.

Antibiot Chemother (1971). 1994;46:38-47. Review. No abstract available.

PMID:
7826038
47.

A rapid, automated microtiter assay for measuring neutralization of HIV-1.

Laal S, Burda S, Sharpe S, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1993 Aug;9(8):781-5.

PMID:
8217345
48.

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Buchbinder A, Zolla-Pazner S, Karwowska S, Gorny MK, Burda ST.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1395. No abstract available.

PMID:
1466965
49.

Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.

Buchbinder A, Karwowska S, Gorny MK, Burda ST, Zolla-Pazner S.

AIDS Res Hum Retroviruses. 1992 Apr;8(4):425-7. No abstract available.

PMID:
1599752

Supplemental Content

Support Center